UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
UNILAB CORPORATION
(Name of Issuer)
Common Stock, Par Value $.01 Per Share
(Title of Class of Securities)
904763208
(CUSIP Number of Class of Securities)
Leo C. Farrenkopf, Jr.
Quest Diagnostics Incorporated
Vice President and Secretary
One Malcolm Avenue
(201) 393-5000
(Name, Address and Telephone Number of Persons Authorized to Receive Notices
and Communications on Behalf of filing persons)
Copy to:
Clare O'Brien
Shearman & Sterling
599 Lexington Avenue
New York, New York 10022
(212) 848-4000
April 2, 2002
(Date of event which requires filing of this statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box [ ].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss. 240.13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 (the "Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 904763208
--------- ----------------------------------------------------------------------
1 Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
QUEST DIAGNOSTICS INCORPORATED
--------- ----------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group
(a): /_/
(b): /_/
--------- ----------------------------------------------------------------------
3 SEC Use Only
--------- ----------------------------------------------------------------------
4 Source of Funds (See Instructions) OO; BK
--------- ----------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e):
--------- ----------------------------------------------------------------------
6 Citizenship or Place of Organization DELAWARE
--------- ----------------------------------------------------------------------
--------------------------------------------------------------------------------
NUMBER OF 7 Sole Voting Power
SHARES 0
BENEFICIALLY ------------------------------------------------
OWNED BY 8 Shared Voting Power
EACH 13,841,178*
REPORTING ------------------------------------------------
PERSON 9 Sole Dispositive Power
WITH 0
------------------------------------------------
10 Shared Dispositive Power
0
--------------------------------------------------------------------------------
--------- ----------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person
13,841,178* shares of common stock
--------- ----------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions):
--------- ----------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11) 41.33%**
--------- ----------------------------------------------------------------------
14 Type of Reporting Person (See Instructions) CO
--------- ----------------------------------------------------------------------
--------------------
* Reflects the number of shares of common stock of Unilab Corporation
collectively held by Kelso Investment Associates VI, L.P. and KEP VI, LLC as of
April 2, 2002, as represented and warranted by such persons in the Stockholders
Agreement (as defined below).
** Based on 33,487,650 shares of common stock of Unilab Corporation outstanding
as of March 25, 2002, as represented and warranted by Unilab Corporation in the
Merger Agreement (as defined below).
2
CUSIP No. 904763208
--------- ----------------------------------------------------------------------
1 Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
QUEST DIAGNOSTICS NEWCO INCORPORATED
--------- ----------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group
(a): /_/
(b): /_/
--------- ----------------------------------------------------------------------
3 SEC Use Only
--------- ----------------------------------------------------------------------
4 Source of Funds (See Instructions) AF; OO; BK
--------- ----------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e):
--------- ----------------------------------------------------------------------
6 Citizenship or Place of Organization DELAWARE
--------- ----------------------------------------------------------------------
--------------------------------------------------------------------------------
NUMBER OF 7 Sole Voting Power
SHARES 0
BENEFICIALLY ------------------------------------------------
OWNED BY 8 Shared Voting Power
EACH 13,841,178*
REPORTING ------------------------------------------------
PERSON 9 Sole Dispositive Power
WITH 0
------------------------------------------------
10 Shared Dispositive Power
0
--------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person
13,841,178* shares of common stock
--------- ----------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions):
--------- ----------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11) 41.33%**
--------- ----------------------------------------------------------------------
14 Type of Reporting Person (See Instructions) CO
--------- ----------------------------------------------------------------------
--------------------
* Reflects the number of shares of common stock of Unilab Corporation
collectively held by Kelso Investment Associates VI, L.P. and KEP VI, LLC as of
April 2, 2002, as represented and warranted by such persons in the Stockholders
Agreement.
** Based on 33,487,650 shares of common stock of Unilab Corporation outstanding
as of March 25, 2002, as represented and warranted by Unilab Corporation in the
Merger Agreement.
3
Item 1. Security and Issuer.
The class of equity securities to which this statement on Schedule 13D
(the "Statement") relates is the common stock, par value $.01 per share (the
"Common Stock"), of Unilab Corporation, a Delaware corporation (the "Issuer").
The principal executive offices of the Issuer are located at 18448 Oxnard
Street, Tarzana, California 91356.
Item 2. Identity and Background.
a. The names of the persons filing this Statement are Quest
Diagnostics Incorporated, a Delaware corporation ("Quest
Diagnostics"), and Quest Diagnostics Newco Incorporated, a
Delaware corporation and a wholly owned subsidiary of Quest
Diagnostics ("Merger Sub" and, together with Quest Diagnostics,
the "Filing Persons").
b. The address of the principal business and the principal executive
offices of each of the Filing Persons is: One Malcolm Avenue,
Teterboro, New Jersey 07608.
c. Quest Diagnostics is a provider of diagnostic testing and related
services for the healthcare industry. Quest Diagnostics offers a
range of clinical laboratory testing services used by physicians
in the detection, diagnosis, evaluation, monitoring and treatment
of diseases and other medical conditions. Quest Diagnostics has a
national network of laboratories and patient service centers.
Merger Sub has no operations and was incorporated solely for the
purpose of the Offer and the Merger (as defined below).
d. During the last five years, neither Quest Diagnostics nor Merger
Sub has been convicted in any criminal proceeding.
e. During the last five years, neither Quest Diagnostics nor Merger
Sub has been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction, as a result of
which proceeding it is or was subject to a judgment, decree or
final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws
or finding any violation with respect to such laws.
f. All of the directors and executive officers of Quest Diagnostics
and Merger Sub are citizens of the United States.
Information regarding the directors and executive officers of Quest
Diagnostics and Merger Sub is set forth on Schedule I and Schedule II,
respectively, attached hereto. During the last five years, to the knowledge of
the Filing Persons, no person named on Schedule I or Schedule II has been (a)
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or (b) a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding
is or was subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, federal or
state securities laws or finding any violation with respect to such laws.
4
Item 3. Source and Amount of Funds or Other Consideration.
On April 2, 2002, Quest Diagnostics, Merger Sub and the Issuer entered
into an Agreement and Plan of Merger (the "Merger Agreement") under which Merger
Sub will commence an exchange offer (the "Offer") to acquire all of the
outstanding shares of Common Stock. In the Offer, the Issuer's stockholders may
elect to receive $26.50 in cash, or 0.3256 of a share of Quest Diagnostics
common stock, in exchange for each of their shares of Common Stock. However, the
aggregate cash consideration payable to the Issuer's stockholders will be
limited to 30% of the total consideration payable for all of the shares of
Common Stock in the Offer and the Merger. After completion of the Offer, Quest
Diagnostics intends to effect a merger of the Issuer with Merger Sub (the
"Merger"). At the effective time of the Merger, each outstanding share of Common
Stock not acquired in the Offer will be converted into 0.3256 of a share of
Quest Diagnostics common stock.
The Offer is not conditioned upon any financing arrangements. Assuming
the Issuer's stockholders elect to receive 30% of the offer consideration in the
form of cash, Quest Diagnostics expects to pay approximately $295 million in
cash to the Issuer's stockholders in connection with the Offer and the Merger.
As described in the immediately preceding paragraph, the remaining portion of
the consideration payable to the Issuer's stockholders in the Offer and the
Merger will be paid in the form of shares of Quest Diagnostics common stock.
Pursuant to a commitment letter dated March 27, 2002, each of Bank of America,
N.A. and Merrill Lynch Capital Corporation have agreed to lend Quest Diagnostics
$275 million as part of a $550 million bridge loan facility that will be
provided to Quest Diagnostics in connection with the Offer and the Merger. The
bridge loan facility will contain customary terms and conditions, including,
without limitation, with respect to fees, indemnification and events of default.
Quest Diagnostics expects to use a portion of the proceeds of the bridge loan
facility to pay the cash consideration and the fees and expenses of the Offer
and the Merger.
Concurrently upon entering into the Merger Agreement, on April 2,
2002, Quest Diagnostics and Merger Sub entered into a Stockholders Agreement
(the "Stockholders Agreement") with Kelso Investment Associates VI, L.P., a
Delaware limited partnership ("LP"), and KEP VI, LLC., a Delaware limited
liability company ("LLC" and, together with LP, "Kelso"). Certain terms of the
Stockholders Agreement are summarized in Item 4 below.
References to, and descriptions of, the Offer, the Merger, the Merger
Agreement, the Stockholders Agreement, the commitment letter and the bridge loan
facility as set forth above in this Item 3 are qualified in their entirety by
reference to the copies of the Merger Agreement, the Stockholders Agreement and
the commitment letter, respectively, included as Exhibits 2.1, 99.2 and 99.4 to
this Statement, and incorporated in this Item 3 in their entirety where such
references and descriptions appear.
Item 4. Purpose of Transaction.
(a) - (b) As described in Item 3 above, pursuant to the Merger
Agreement, Merger Sub shall commence the Offer to acquire all of the outstanding
shares of Common Stock. The
5
purpose of the Offer is for Quest Diagnostics to acquire control of, and
ultimately the entire common equity interest in, the Issuer. Upon completion of
the Offer, Quest Diagnostics shall cause Merger Sub to be merged with the
Issuer. The purpose of the Merger is for Quest Diagnostics to acquire all of the
shares of Common Stock that are not exchanged in the Offer.
As an inducement for Quest Diagnostics and Merger Sub to enter into
the Merger Agreement and as a condition thereof, Kelso entered into the
Stockholders Agreement. Under the Stockholders Agreement, Kelso has agreed,
among other things, to:
(i) promptly tender into the Offer, and not withdraw, all of
the shares of Common Stock held by Kelso;
(ii) vote all of the shares of Common Stock held by Kelso
at any meeting of the Issuer's stockholders, or in
any action by consent of the Issuer's stockholders,
in favor of adoption of the Merger Agreement and the
transactions contemplated thereby and against any
action that could reasonably be expected to adversely
affect the Offer or the Merger;
(iii) in the event of a failure by Kelso to comply with its
obligations described in clause (ii) above, grant an
irrevocable proxy to Quest Diagnostics to vote all of
the shares of Common Stock held by Kelso at any
meeting of the Issuer's stockholders, or in any
action by consent of the Issuer's stockholders, in
favor of adoption of the Merger Agreement and the
transactions contemplated thereby and against any
action that could reasonably be expected to adversely
affect the Offer or the Merger;
(iv) in the event the Merger Agreement is terminated in
certain circumstances, sell to Quest Diagnostics all
of the shares of Common Stock held by Kelso for a per
share purchase price of $26.50; and
(v) not sell, transfer or tender (except pursuant to the
Offer) any of the shares of Common Stock held by
Kelso until the earlier of the effective time of the
Merger or the close of business on the 45th day after
the termination of the Merger Agreement.
Each of the foregoing covenants is also applicable to any
shares of Common Stock acquired by Kelso after April 2, 2002.
(c) Not applicable.
(d) Upon the purchase by Merger Sub of shares of Common Stock
pursuant to the Offer, Quest Diagnostics shall be entitled to designate the
number of directors, rounded up to the next whole number, on the Issuer's Board
of Directors (the "Board") equal to the product of the total number of directors
on the Board (giving effect to the directors elected pursuant to Section 2.03 of
the Merger Agreement) multiplied by the percentage that the number of shares of
Common Stock beneficially owned by Quest Diagnostics and Merger Sub (following
such
6
purchase) bears to the total number of shares of Common Stock then outstanding.
In the Merger Agreement, the Issuer has agreed that, at such time, it shall take
all actions necessary to cause Quest Diagnostics' designees to be elected as
directors of the Issuer, including increasing the size of the Board and securing
the resignations of incumbent directors. The Merger Agreement also provides
that, at such time, the Issuer shall use its best efforts to cause persons
designated by Quest Diagnostics to constitute the number of members, rounded up
to the next whole number, on (a) each committee of the Board, (b) each board of
directors of each subsidiary of the Issuer, and (c) each committee of each such
board that represents the same percentage as such individuals represent on the
Board, in each case only to the extent permitted by applicable law.
Notwithstanding the foregoing, until the effective time of the Merger, the Board
shall have at least two directors who were directors of the Issuer on the date
of the Merger Agreement.
Upon consummation of the Merger, the directors of Merger Sub shall
become the directors of the surviving corporation. At the effective time of the
Merger, the officers of the Issuer immediately prior to the effective time of
the Merger shall be the officers of the surviving corporation, until their
respective successors are duly elected or appointed and qualified.
(e) None, other than the change in the number of outstanding shares
of Common Stock as contemplated by the Merger Agreement.
(f) Not applicable.
(g) If the Merger of the Issuer with and into Merger Sub is
consummated as planned, the certificate of incorporation and by-laws of Merger
Sub shall be the certificate of incorporation and by-laws of the surviving
corporation resulting from the Merger.
(h) If the Merger is consummated as planned, the Common Stock will
cease to be authorized to be listed on the Nasdaq National Market or any other
quotation system or exchange.
(i) If the Merger is consummated as planned, the Common Stock will
be deregistered pursuant to Section 12(g)(4) of the Securities Exchange Act of
1934, as amended.
(j) Other than as described above, the Filing Persons currently have
no plan or proposal which relates to, or may result in, any of the matters
listed in Items 4(a)-(i) of this Statement (although the Filing Persons reserve
the right to develop such plans).
References to, and descriptions of, the Offer, the Merger, the Merger
Agreement and the Stockholders Agreement as set forth above in this Item 4 are
qualified in their entirety by reference to the copies of the Merger Agreement
and the Stockholders Agreement, respectively, included as Exhibits 2.1 and 99.2
to this Statement, and incorporated in this Item 4 in their entirety where such
references and descriptions appear.
Item 5. Interest in Securities of the Issuer.
7
(a)-(b) As a result of the Stockholders Agreement, the Filing Persons
may be deemed to be the beneficial owner of 13,841,178 shares of Common Stock,
representing 41.33% of the outstanding shares of Common Stock. The calculation
of the foregoing percentage is based on the number of shares of Common Stock
outstanding as of March 25, 2002, as represented and warranted by the Issuer in
the Merger Agreement. The Filing Persons may be deemed to have shared power to
vote such shares of Common Stock with respect to the limited matters described
in clauses (a) and (b) of Item 4 above. However, the Filing Persons (i) are not
entitled to any rights as a stockholder of the Issuer with respect to such
shares of Common Stock and (ii) disclaim any beneficial ownership of the shares
of Common Stock that are covered by the Stockholders Agreement. The Filing
Person do not have the power to dispose of such shares of Comon Stock.
Except as set forth herein, to the knowledge of the Filing Persons, no
director or executive officer of the Filing Persons beneficially owns any shares
of Common Stock.
(c) The Filing Persons have not effected any transaction in the
shares of Common Stock during the past sixty days. To the knowledge of the
Filing Persons, no person named in either Schedule I or Schedule II has effected
any transaction in the shares of Common Stock during the past sixty days.
(d) To the knowledge of the Filing Persons, Kelso has the right to
receive, or the power to direct the receipt of, dividends in respect of its
shares of Common Stock. Other than as a result of the restrictions on transfer
described under Item 4(a)-(b) above, which restrictions preclude the sale,
transfer or tender of the shares of Common Stock held by Kelso until the earlier
of the effective time of the Merger or the close of business on the 45th day
after the termination of the Merger Agreement, to the knowledge of the Filing
Persons, Kelso has the power to direct the proceeds from the sale of such shares
of Common Stock.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understanding or Relationships With
Respect to Securities of the Issuer.
Other than the Merger Agreement and the Stockholders Agreement, to the
knowledge of the Filing Persons, there are no contracts, arrangements,
understandings or relationships among the persons named in Item 2 and between
such persons and any person with respect to any securities of the Issuer,
including but not limited to, transfer or voting of any of the securities,
finder's fees, joint ventures, loan or option arrangement, puts or calls,
guarantees of profits, division of profits or loss, or the giving or withholding
of proxies.
Item 7. Material to be Filed as Exhibits.
8
2.1 Agreement and Plan of Merger, dated as of April 2, 2002, among Quest
Diagnostics, Merger Sub and the Issuer.*
99.2 Stockholders Agreement, dated as of April 2, 2002, among Quest
Diagnostics, Merger Sub and Kelso.**
99.3 Joint Filing Agreement, dated as of April 12, 2002, among Quest
Diagnostics and Merger Sub.
99.4 Commitment Letter, dated as of March 27, 2002, between Quest
Diagnostics, Bank of America, N.A. and Merrill Lynch Capital
Corporation.
-----------------------
* Incorporated herein by reference to Exhibit 2.1 of Quest Diagnostics' Current
Report on Form 8-K filed with the Commission on April 2, 2002.
** Incorporated herein by reference to Exhibit 99.2 of Quest Diagnostics'
Current Report on Form 8-K filed with the Commission on April 2, 2002.
9
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: April 12, 2002
QUEST DIAGNOSTICS INCORPORATED
By: /s/ Leo C. Farrenkopf, Jr.
---------------------------------
Name: Leo C. Farrenkopf, Jr.
Title: Vice President and
Secretary
QUEST DIAGNOSTICS NEWCO INCORPORATED
By: /s/ Leo C. Farrenkopf, Jr.
---------------------------------
Name: Leo C. Farrenkopf, Jr.
Title: Secretary
EXHIBIT INDEX
2.1 Agreement and Plan of Merger, dated as of April 2, 2002, among
Quest Diagnostics, Merger Sub and the Issuer.*
99.2 Stockholders Agreement, dated as of April 2, 2002, among Quest
Diagnostics, Merger Sub and Kelso.**
99.3 Joint Filing Agreement, dated as of April 12, 2002, among Quest
Diagnostics and Merger Sub.
99.4 Commitment Letter, dated as of March 27, 2002, between Quest
Diagnostics, Bank of America, N.A. and Merrill Lynch Capital Corporation.
-----------------------
* Incorporated herein by reference to Exhibit 2.1 of Quest Diagnostics' Current
Report on Form 8-K filed with the Commission on April 2, 2002.
** Incorporated herein by reference to Exhibit 99.2 of Quest Diagnostics'
Current Report on Form 8-K filed with the Commission on April 2, 2002.
SCHEDULE I
DIRECTORS AND EXECUTIVE OFFICERS OF QUEST DIAGNOSTICS INCORPORATED
The following table sets forth the name and current principal
occupation or employment, and material occupations, positions, offices or
employments for the past five years of each director and executive officer of
Quest Diagnostics. Unless otherwise indicated, the current business address of
each person is Quest Diagnostics Incorporated, One Malcolm Avenue, Teterboro, NJ
07608.
Name Quest Diagnostics Directors and Executive Officers
---- Present Principal Occupation or Employment;
Material Positions Held During the Past Five Years
--------------------------------------------------
Kenneth D. Brody Mr. Brody is the founding partner of Winslow Partners
LLC, a Washington, D.C. private investment firm with
an address at 1300 Connecticut Avenue, N.W., 8th
Floor, Washington, D.C. 20036. He is also the
co-founder and principal of Taconic Capital Advisors,
an investment adviser firm. From 1993 to early 1996,
he was the chairman and president of the
Export-Import Bank of the United States, a position
to which he was appointed by President Clinton. From
1971 to 1991, Mr. Brody was with Goldman, Sachs &
Co., where he was a partner and member of the
management committee. Mr. Brody is a director of
Federal Realty Investment Trust. Mr. Brody has been a
director of Quest Diagnostics since January 1997.
William F. Buehler Mr. Buehler recently retired as vice chairman of
Xerox Corporation, which he joined in 1991. Prior to
joining Xerox, Mr. Buehler spent 27 years with AT&T,
primarily in sales, marketing and general management
positions. Mr. Buehler is a director of A.O. Smith.
Mr. Buehler has been a director of Quest Diagnostics
since July 1998.
Van C. Campbell Mr. Campbell retired in 1999 as vice chairman of
Corning Incorporated, which he joined in 1965. He was
elected treasurer in 1972, a vice president in 1973,
financial vice president in 1975 and senior vice
president for finance in 1980. He became general
manager of the Consumer Products Division in 1981.
Mr. Campbell was elected vice chairman and a director
in 1983 and during 1995 was appointed to the
additional position of chairman of Corning Life
Sciences Inc. He is a director of Armstrong World
Industries, Inc. Mr. Campbell has been a director of
Quest Diagnostics since January 1991.
Mary A. Cirillo Ms. Cirillo is chairperson and chief executive
officer of OPCENTER, which provides help desk and
network operations services. OPCENTER's address is
660 Madison Avenue, 14th Floor, New York, New York
10021. She was chief executive officer of Global
Institutional Services of Deutsche Bank from July
1999 until February 2000. Previously, she served as
executive vice president and managing director of
Bankers Trust Company (which was acquired by Deutsche
Bank), which she joined in 1997. From 1977 to 1997,
she was with Citibank, N.A., most recently serving as
senior vice president.
Ms. Cirillo is on the advisory board of Cisco
Systems, Inc. and is a director of Digital Island
Inc. Ms. Cirillo has been a director of Quest
Diagnostics since April 1997.
William R. Grant Mr. Grant has been chairman of Galen Associates, a
New York investment firm, since 1989. Galen
Associates' address is 610 Fifth Avenue New York, New
York 10020. From 1987 to 1989 he was chairman of New
York Life International and from 1979 to 1987 of
MacKay-Shields Financial Corp. He is also a former
director and vice-chairman of SmithKline Beecham plc,
and is currently a director of Allergan, Inc., Massey
Energy Co., Ocular Sciences, Inc. and Vasogen Inc. He
has been a director of Quest Diagnostics since August
1999.
Rosanne Haggerty Ms. Haggerty is the founder and executive director of
Common Ground, a not-for-profit housing development
and management organization with an address at 14
East 28th Street, New York, New York 10016. Prior to
founding Common Ground, she was the coordinator of
housing development at Brooklyn Catholic Charities.
Ms. Haggerty is a 2001 MacArthur Foundation Fellow.
Ms. Haggerty has been a director of Quest Diagnostics
since February 2002.
Dan C. Stanzione Mr. Stanzione is president emeritus of Bell
Laboratories at Lucent Technologies Incorporated,
3008 Southview Drive, Stuart, Florida 34996. Dr.
Stanzione began his career in 1972 with Bell Labs,
where he led the teams working on the first
microprocessors and digital signal processors. He was
appointed president of Network Systems, Lucent's
largest business unit, in 1996 and was appointed
chief operating officer of Lucent in 1997. Dr.
Stanzione is a director of Avaya Inc. Dr. Stanzione
has been a director of Quest Diagnostics since
January 1997.
Gail R. Wilensky Ms. Wilensky is the John M. Olin Senior Fellow at
Project HOPE, an international non-profit health
foundation, which she joined in 1993. The address of
Project Hope is Suite 600, 7500 Old Georgetown Road,
Bethesda, Maryland 20814. She is currently the chair
of the Medicare Payment Advisory Commission, which
advises Congress on all issues relating to Medicare.
From 1995 to 1997 she chaired the Physician Payment
Review Commission, which advised Congress on
physician payment and other Medicare issues. In 1992
and 1993, Dr. Wilensky served as a deputy assistant
to the President for policy development relating to
health and welfare issues. From 1990 to 1992, she was
the administrator of the Health Care Financing
Administration where she directed the Medicare and
Medicaid programs. Dr. Wilensky is a director of
Advanced Tissue Sciences Inc., Gentiva Health
Services, Inc., Manor Care Inc., Syncor Corporation
and United Healthcare Corporation. Dr. Wilensky has
been a director of Quest Diagnostics since January
1997.
2
John B. Ziegler Mr. Ziegler is the president, Worldwide Consumer
Healthcare, of GlaxoSmithKline (the parent of
SmithKline Beecham plc), One Franklin Plaza,
Philadelphia, Pennsylvania 19102. Mr. Ziegler joined
SmithKline Beecham in 1991 as the head of SB Consumer
Healthcare-North American Division. He became
executive vice president of SmithKline Beecham in
1996 and assumed his current responsibilities in
1998. He has been a director of Quest Diagnostics
since May 2000.
Kenneth W. Freeman Mr. Freeman is chairman of the Board and chief
executive officer of Quest Diagnostics. Mr. Freeman
joined Quest Diagnostics in May 1995 as president and
chief executive officer, was elected a director in
July 1995 and was elected chairman of the Board in
December 1996. Prior to 1995, he served in a variety
of financial and managerial positions at Corning,
which he joined in 1972. He was elected controller
and a vice president of Corning in 1985, senior vice
president in 1987, general manager of the Science
Products Division in 1989 and executive vice
president in 1993. He was appointed president and
chief executive officer of Corning Asahi Video
Products Company in 1990.
Surya N. Mohapatra, Mr. Mohapatra is president and chief operating
Ph.D. officer. Prior to joining Quest Diagnostics in
February 1999 as senior vice president and chief
operating officer, he was senior vice president of
Picker International, a worldwide leader in advanced
medical imaging technologies, where he served in
various executive positions during his 18-year
tenure.
Lucia L. Quinn Ms. Quinn is senior vice president for Advanced
Diagnostics. Ms. Quinn has overall responsibility for
Science and Innovation, Business Development,
Pharmaceutical Services and Consumer Health. Ms.
Quinn joined Quest Diagnostics in April 2001 as vice
president, Developing Businesses. From 1999 through
April 2001 she was with Allied Signal/Honeywell,
serving most recently as vice president Strategic
Marketing. From 1989 through 1999, Ms. Quinn was
employed by Digital Equipment Corporation/Compaq,
most recently serving as vice president - Corporate
Strategy. She assumed her current responsibilities in
October 2001.
Richard L. Bevan Mr. Bevan is corporate vice president for Human
Resources. From 1982 until August 1999, Mr. Bevan
served in a variety of human resources positions for
SmithKline Beecham's pharmaceutical and clinical
laboratory businesses, most recently serving as vice
president and director of human resources-operations
for SBCL. Mr. Bevan was appointed corporate vice
president for Human Resource Strategy and Development
in August 1999, and to his present position in
January 2001.
Catherine Doherty Ms. Doherty is vice president for Communications and
Public Affairs. Ms. Doherty has overall
responsibility for internal and external
communications and government affairs. Ms. Doherty
has been employed by Quest Diagnostics since 1990.
She served as chief accounting officer from 1996
until July 2000, when she became vice president -
Investor Relations. Ms. Doherty assumed her current
responsibilities in November 2001.
3
Robert A. Hagemann Mr. Hagemann is vice president and chief financial
officer. He joined Corning Life Sciences, Inc., in
1992, where he held a variety of senior financial
positions before being named vice president and
corporate controller of Quest Diagnostics in 1996.
Prior to joining Quest Diagnostics, Mr. Hagemann was
employed by Prime Hospitality, Inc. and Crompton &
Knowles, Inc. in senior financial positions. He was
also previously associated with Ernst & Young. Mr.
Hagemann assumed his present responsibilities in
August 1998.
Gerald C. Marrone Mr. Marrone is senior vice president, Administration
and chief information officer. Prior to joining Quest
Diagnostics in November 1997 as chief information
officer, Mr. Marrone was with Citibank, N.A. for 12
years. During his tenure he was most recently vice
president, division executive for Citibank's Global
Production Support Division. While at Citibank, he
was also the chief information officer of Citibank's
Global Cash Management business. Prior to joining
Citibank, he was the chief information officer for
Memorial Sloan-Kettering Cancer Center in New York
for five years.
Michael E. Prevoznik Mr. Prevoznik is vice president for Legal and
Compliance and general counsel. Prior to joining
SmithKline Beecham Clinical Laboratories, Inc. in
1994 as its chief legal compliance officer, Mr.
Prevoznik was with Dechert Price & Rhodes. In 1996,
he became vice president and chief legal compliance
officer for SmithKline Beecham Healthcare Services.
In 1998, he was appointed vice president, Compliance
for SmithKline Beecham, assuming additional
responsibilities for coordinating all compliance
activities within SmithKline Beecham worldwide. Mr.
Prevoznik assumed his current responsibilities with
Quest Diagnostics in August 1999.
4
SCHEDULE II
DIRECTORS AND EXECUTIVE OFFICERS OF QUEST DIAGNOSTICS
NEWCO INCORPORATED
The following table sets forth the name and current principal
occupation or employment, and material occupations, positions, offices or
employments for the past five years of each director and executive officer of
Merger Sub. Unless otherwise indicated, the current business address of each
person is Quest Diagnostics Newco Incorporated c/o Quest Diagnostics
Incorporated, One Malcolm Avenue, Teterboro, NJ 07608.
Quest Diagnostics Newco Incorporated Directors and
Executive Officers Present Principal Occupation or
Employment; Material Positions Held During the Past
Name Five Years
---- ----------
Kenneth W. Freeman Mr. Freeman is chief executive officer of Merger Sub.
Mr. Freeman is also chairman of the Board and chief
executive officer of Quest Diagnostics. Mr. Freeman
joined Quest Diagnostics in May 1995 as president and
chief executive officer, was elected a director in
July 1995 and was elected chairman of the Board in
December 1996. Prior to 1995, he served in a variety
of financial and managerial positions at Corning,
which he joined in 1972. He was elected controller
and a vice president of Corning in 1985, senior vice
president in 1987, general manager of the Science
Products Division in 1989 and executive vice
president in 1993. He was appointed president and
chief executive Officer of Corning Asahi Video
Products Company in 1990.
Surya N. Mohapatra, Mr. Mohapatra is a director of Merger Sub, as well as
Ph.D. president and chief operating officer of Merger Sub.
Prior to joining Quest Diagnostics in February 1999
as senior vice president and chief operating officer,
he was senior vice president of Picker International,
a worldwide leader in advanced medical imaging
technologies, where he served in various executive
positions during his 18-year tenure.
Robert A. Hagemann Mr. Hagemann is a director of Merger Sub, as well as
vice president and chief financial officer of Merger
Sub. He joined Corning Life Sciences, Inc., in 1992,
where he held a variety of senior financial positions
before being named vice president and corporate
controller of Quest Diagnostics in 1996. Prior to
joining Quest Diagnostics, Mr. Hagemann was employed
by Prime Hospitality, Inc. and Crompton & Knowles,
Inc. in senior financial positions. He was also
previously associated with Ernst & Young. Mr.
Hagemann assumed his present responsibilities in
August 1998.
5